Illicit Chinese Pipeline Sends Unapproved Weight-Loss Peptide into U.S. Homes
An illegal supply chain is moving the experimental obesity drug retatrutide from Chinese manufacturers into American consumers, prompting calls for a coordinated enforcement response.
A covert supply chain is delivering the experimental GLP-1 drug retatrutide, known as “reta,” from Chinese chemical producers to U.S. buyers, despite the absence of FDA approval. The scheme relies on falsified customs declarations, rebranding by U.S. middlemen, and the use of coded identifiers such as “GLP-3 RT,” accompanied by dosing instructions and “research use only” labels. Evidence from blockchain analysts at Chainalysis and TRM Labs links the proceeds of U.S. peptide sales back to Chinese firms that previously supplied fentanyl precursors.
A Customs and Border Protection operation in Cincinnati seized over 300 cartons containing roughly 5,000 peptide shipments, including retatrutide. Lawmakers and officials contend that the illicit pipeline poses a national-security risk, urging the Department of Homeland Security, Department of Justice, FDA and state authorities to launch a comprehensive crackdown. They also call on tech platforms, payment processors and shippers to halt facilitation of the trade, warning that the current focus on one drug could precede broader illicit imports.
Why it matters
Unapproved drugs entering homes bypass safety checks, endangering public health and exposing a vulnerable supply chain.
In this story
